|
|
|
Winning Global Customers through Innovative Quality Pharmaceutical Products
|
|
|
|
|
|
Ind-Swift Laboratories Limited undergoes successful USFDA audit |
Ind-Swift Laboratories Ltd. has successfully completed USFDA inspection for Clarithromycin, Active Pharmaceutical Ingredient (API) manufacturing facility. Ind-Swift Laboratories Inc. USA, a wholly owned subsidiary of Ind-Swift Laboratories was instrumental in achieving this milestone, said N.R. Munjal, Managing Director.
This would enable us to roll out our API’s in the North American market. Ind Swift Laboratories Inc. has partnered with top US generic companies for generic pharmaceutical business. We are also working on alliances with biotechnology companies in North America which will fuel our long term growth strategy said Vikas Narendra, President Ind-Swift Laboratories Inc.
Ind-Swift has already filed 10 Drug Master Files (DMF’s) and plans to file a significant number of DMF’s with USFDA during next financial year. This will pave way for the company to enter the
US
market, which is biggest generic drugs market in the World.
Ind-Swift Laboratories has a significant presence in more than 45 countries, in addition to a strong position in the domestic market. Its research and development centre employs over 150 scientists. The facility has already received the
COS
and TGA certifications.
Clarithromycin is a Macrolide Antibiotic Molecule used in the treatment of the lower respiratory tract infections. The Macrolides have a World Market Size of US$ 1.3 bn. Ind-Swift is one of the largest manufacturer of Clarithromycin after the innovator.
|
|
|
|